Dr. Tse-Wen Chang, President

Please see Founder

Dr. Hsing-Mao Art Chu, CEO

Dr. Chu obtained his B.Sc. degree from Chang Gung University, M.Sc. degree from National Yang-Ming University, and Ph.D. degree from National Taiwan University. He started his postdoctoral research in the Institute of Biological Chemistry, Academia Sinica, and joined Dr. Chang’s laboratory in the Genomics Research Center, Academia Sinica in 2011 to study various antibody engineering methodologies and to work on CεmX and anti-CεmX antibodies.

He was invited to join Immunwork to lead the research team in 2015. He works as the CEO of T-E Meds and Vice President of R&D of Immunwork now.

Ms. Ying-Rong Lai, Vice President of Administration & Executive Assistant to Chairman

Ms. Lai obtained her Master degree in Biotechnology Management from National Taiwan University. After graduating from university in 1998, she worked in several fields, including cost control and estimation within the company, participating in biddings of multiple industries, spending several years in the high education system and engaged in trade operation and finally entered the financial system. According to her excellent management experiences in several business sectors, she was invited to work as the financial executive.  

From 2004 to 2014, she was a key manager of investment at Taishin International Commercial Bank and at Yuanta Commercial Bank and won a number of service excellence awards. In 2014, she was invited by Dr. Tse-Wen Chang to join Immunwork and was responsible for assisting in establishment, administrative and financial affairs of T-E Pharma Holding. She works as the Vice President of Administration & Executive Assistant to the Chairman now.

Dr. Chi-Jiun Peng, Director, Process Development and CMC

Dr. Peng received his B.Sc. and M.Sc. degrees from Yang-Ming University in 1999 and 2001.

He then joined the Tri-Service General Hospital as a radiochemist in charge of new drug development, clinical drug production, and clinical trials. In 2013, he joined Super Laboratory Inc. as Director of Analytical Chemistry Laboratory. In 2014, he began Ph.D. studies in the Department of Chemistry, National Taiwan University doing research on glycoprotein vaccines.

After receiving Ph.D. in 2019, he joined Immunwork as a manager and then served as a director of process development of T-E Meds in 2022, responsible for CMC and manufacturing.

Dr. Kun-Po Li, Director, Business Development

Dr. Li received B.Sc. and M.Sc. degrees from National Taiwan University and Ph.D. degree in Immunology from University of Cincinnati.

Before joining Immunwork in 2020, Dr. Li worked at the Greater Boston Campus of Sanofi, where he was a project manager, leading translational medicine studies of multiple products in immuno-oncology, autoimmune, and rare diseases therapeutic areas. Prior to Sanofi, Dr. Li worked at Compass Therapeutics, Inc. to support research of therapeutic antibodies and bi-specific antibodies.

Dr. Li is responsible for external collaborations with T-E Pharma Holding.

Dr. Cédric Grauffel, Manager, T-E Drug Molecular Design

Dr. Grauffel received his Ph.D. in Chemistry at the University of Strasbourg, France in 2009 and did postdoctoral research on peripheral membrane proteins and protease inhibitors in the University of Bergen, Norway in 2010-13.

He came to the Institute of Biomedical Sciences, Academia Sinica in 2013, where he worked on metal competition in proteins and aspects of drug design until 2022, when he was hired by T-E Meds as a manager in charge of the design of a new generation of T-E pharmaceuticals.

Scroll to Top